Calculation Methodology. No adjustment in the Conversion Price need be made unless the adjustment would require an increase or decrease of at least 1% in the Conversion Price then in effect, provided that any adjustment that would otherwise be required to be made shall be carried forward and taken into account in any subsequent adjustment. Except as stated in this Article VI, the Conversion Rate will not be adjusted for the issuance of Common Stock or any securities convertible into or exchangeable for Common Stock or carrying the right to purchase any of the foregoing. Any adjustments that are made shall be carried forward and taken into account in any subsequent adjustment. All calculations under Article V and Section 6.06 hereof and this Section 6.07 shall be made to the nearest cent or to the nearest 1/10,000th of a share, as the case may be.
Calculation Methodology. Except as stated in this Article IX, the Conversion Rate will not be adjusted for the issuance of Common Stock or any securities convertible into or exchangeable for Common Stock or carrying the right to purchase any of the foregoing. If after an adjustment a Holder of a Note upon conversion of such Note may receive shares of two or more classes of Capital Stock of the Company, the Conversion Rate shall thereafter be subject to adjustment upon the occurrence of an action with respect to any such class of Capital Stock as is contemplated by this Article IX with respect to the Common Stock, on terms comparable to those applicable to Common Stock in this Article IX. All calculations under Article VIII, Section 9.8 and this Section 9.9 shall be made to the nearest cent or to the nearest 1/10,000th of a share, as the case may be.
Calculation Methodology. No adjustment in the Conversion Price need be made unless the adjustment would require an increase or decrease of at least 1% in the Conversion Price then in effect provided that any adjustment that would otherwise be required to be made shall be carried forward and taken into account in any subsequent adjustment. Except as stated in Section 2.07, the Conversion Rate will not be adjusted for the issuance of Common Stock or any securities convertible into or exchangeable for Common Stock or carrying the right to purchase any of the foregoing. Any adjustments that are made shall be carried forward and taken into account in any subsequent adjustment. All calculations under Sections 2.06, 2.07 and this Section 2.08 shall be made to the nearest cent or to the nearest 1/10,000th of a share, as the case may be.
Calculation Methodology. The parties hereto agree that no amount shall be (or is intended to be) included, in whole or in part (either as an increase or a reduction), more than once in the calculation of the Final Calculations or any other calculated amount pursuant to this Agreement. All of the amounts set forth on the Estimated Schedule and the Final Calculations (and the individual elements thereof, as applicable) shall be determined in accordance with GAAP and on a basis consistent with the accounting practices and procedures used to prepare the Financial Statements for the 2017 fiscal year.
Calculation Methodology. The State’s performance for any given Performance Year will be measured using the Quality Payment Program quality measures Quality ID # 001: “Diabetes: Hemoglobin A1c Poor Control”, Quality ID #236: “Controlling High Blood Pressure”, and Quality ID #479: “All-cause Unplanned Admissions for Patients with Multiple Chronic Conditions”. The target for each measure will be at least between 70th and 80th percentiles using Quality Payment Program quality measure benchmarks based on the comparison to the national Medicare performance percentile information.
Calculation Methodology. The State’s performance for any given Performance Year will be measured using the Quality Payment Program quality measure and specifications for Quality ID #226: “Tobacco Use: Screening and Cessation Intervention”. The milestone’s performance will include Vermont All-payer Beneficiaries who are also aligned to a Vermont ACO payer program that reports this measure. The target will be at least between the 70th and 80th percentiles used for the Quality Payment Program quality measure benchmarks based on the comparison to the national Medicare performance percentile information. The following steps will be done to determine Vermont’s performance on this milestone: • Assign percentile to each of the payers for the measure as compared to national Medicare performance percentile information. • Average the percentiles for each of the payers weighted by the relative proportion of attributed population. • Determine whether the percentile is between the Medicare 70th and 80th percentiles for that Performance Year. If multi-payer national benchmarks become available, CMS and Vermont may compare Vermont’s performance to these benchmarks, instead of using national Medicare performance. CMS and Vermont agree to regularly assess the availability of multi-payer national benchmarks.
Calculation Methodology. The percentage of Vermont All-payer Scale Target Beneficiaries and Vermont Medicare Beneficiaries aligned to a Scale Target ACO Initiative will be calculated as follows:
Calculation Methodology. The State’s performance, measured as an age-adjusted rate per 100,000 Vermont residents, will be calculated using the Centers for Disease Control (CDC) National Vital Statistics System Mortality File’s methodology and data or, as determined by CMS, a comparable methodology and data source for calculating deaths related to drug overdose.
Calculation Methodology. The State’s performance will be calculated, using the CDC BRFSS questionnaire, as the percent of Vermont resident respondents who answer “yes” to the following question: “Do you have one person you think of as your personal doctor or health care provider?”
Calculation Methodology. The State’s performance for any given Performance Year will be measured using Vermont Department of Health’s hospital discharge data and counting the number of ED visits at Vermont hospitals with a primary diagnosis of mental health or substance abuse condition.
